PT  - JOURNAL ARTICLE
AU  - Diane Apostolopoulos
AU  - Rangi Kandane-Rathnayake
AU  - Sudha Raghunath
AU  - Alberta Hoi
AU  - Mandana Nikpour
AU  - Eric F Morand
TI  - Independent association of glucocorticoids with damage accrual in SLE
AID  - 10.1136/lupus-2016-000157
DP  - 2016 Nov 01
TA  - Lupus Science & Medicine
PG  - e000157
VI  - 3
IP  - 1
4099  - http://lupus.bmj.com/content/3/1/e000157.short
4100  - http://lupus.bmj.com/content/3/1/e000157.full
AB  - Objectives To determine factors associated with damage accrual in a prospective cohort of patients with SLE.Methods Patients with SLE who attended the Lupus Clinic at Monash Health, Australia, between 2007 and 2013 were studied. Clinical variables included disease activity (Systemic Lupus Erythematosus Disease Activity Index-2K, SLEDAI-2K), time-adjusted mean SLEDAI, cumulative glucocorticoid dose and organ damage (Systemic Lupus International Collaborating Clinics Damage Index (SDI)). Multivariate logistic regression analyses were performed to identify factors associated with damage accrual.Results A total of 162 patients were observed over a median (IQR) 3.6 (2.0–4.7) years. Seventy-five per cent (n=121) of patients received glucocorticoids. Damage accrual was significantly more frequent in glucocorticoid-exposed patients (42% vs 15%, p<0.01). Higher glucocorticoid exposure was independently associated with overall damage accrual after controlling for factors including ethnicity and disease activity and was significant at time-adjusted mean doses above 4.42 mg prednisolone/day; the OR of damage accrual in patients in the highest quartile of cumulative glucocorticoid exposure was over 10. Glucocorticoid exposure was independently associated with damage accrual in glucocorticoid-related and non-glucocorticoid related domains of the SDI.Conclusions Glucocorticoid use is independently associated with the accrual of damage in SLE, including in non-glucocorticoid related domains.